Description

LUMRYZ® (sodium oxybate) 6g: Once-Nightly Narcolepsy Treatment lumryz dosage

lumryz dosage

What is LUMRYZ?

LUMRYZ (sodium oxybate) for extended-release oral suspension is a prescription medication that contains the active ingredient sodium oxybate, which is the sodium salt of gamma-hydroxybutyrate (GHB) . It is a central nervous system (CNS) depressant that works by modulating sleep-wake regulation to reduce the symptoms of narcolepsy . The extended-release technology allows for a single, once-nightly dose to be taken at bedtime, providing therapeutic exposure throughout the night .

What is LUMRYZ Used For?

LUMRYZ is indicated for the treatment of two primary symptoms in patients 7 years of age and older with narcolepsy :

• Cataplexy: The sudden, transient loss of muscle tone often triggered by strong emotions like laughter or surprise.

• Excessive Daytime Sleepiness (EDS): Overwhelming and persistent daytime sleepiness, a cardinal symptom of narcolepsy.

Who is LUMRYZ For? lumryz narcolepsy

LUMRYZ is for patients aged 7 years and older who have been diagnosed with narcolepsy and experience cataplexy or EDS . It is typically prescribed by a neurologist or sleep specialist. It is also for patients who may find the twice-nightly dosing schedule of other sodium oxybate medications burdensome . LUMRYZ is not for:

• Individuals without a formal narcolepsy diagnosis.

• Patients under 7 years of age .

• Patients with succinic semialdehyde dehydrogenase deficiency .

• Individuals who are also taking sedative hypnotics or consuming alcohol .

What Makes LUMRYZ Different from Other Oxybate Treatments? lumryz medication

The key differentiator for LUMRYZ is its once-nightly dosing . Traditional immediate-release oxybate medications (e.g., Xyrem) require a twice-nightly dosing schedule, where patients must take their first dose at bedtime and then wake up 2.5 to 4 hours later to take the second dose . This middle-of-the-night awakening can be highly disruptive and is a significant burden for many patients . LUMRYZ uses an extended-release mechanism to deliver the full therapeutic dose in a single preparation, aiming to improve patient convenience and adherence without compromising efficacy .

What is the Recommended Dosage for LUMRYZ? lumryz sodium oxybate

Dosing for LUMRYZ is individualized and should be strictly managed by a healthcare professional .

• Adults: The recommended starting dose is 4.5 g once nightly. The dosage is then increased in 1.5 g increments at weekly intervals, based on efficacy and tolerability, to a recommended range of 6 g to 9 g once nightly .

• Pediatric Patients (7 Years and Older):

  • Weighing at least 45 kg: The starting dose is 4.5 g once nightly, titrated to a maximum of 9 g once nightly.

  • Weighing less than 45 kg: The recommended starting dose cannot be achieved with the available strengths of LUMRYZ, so another sodium oxybate product should be used to initiate treatment .

How is LUMRYZ Taken? lumryz dosage

Proper administration is crucial for the safe and effective use of LUMRYZ .

1. Preparation: Prepare the dose of LUMRYZ just before bedtime. The powder from the packet must be suspended in approximately ⅓ cup (about 80 mL) of water in the specially provided mixing cup. A calorie-free drink mix or flavored water enhancer may be added. Do not use hot water .

2. Timing: Take the dose at least 2 hours after eating .

3. Posture: Take LUMRYZ while sitting or lying in bed and lie down immediately after ingestion. The medication can cause a rapid onset of sleep, often within 5 to 15 minutes, even without feeling drowsy . Patients should remain in bed after taking it.

Product Benefits

(All benefits listed are derived from manufacturer clinical trial data and prescribing information)

Verified Benefits (Based on Phase 3 REST-ON Clinical Trial Data):

• Increased Daytime Wakefulness: In a clinical trial, once-nightly LUMRYZ significantly improved the ability to stay awake during the day, as measured by the Maintenance of Wakefulness Test (MWT), compared to placebo .

• Reduced Cataplexy Attacks: LUMRYZ demonstrated a statistically significant and clinically meaningful reduction in the mean number of weekly cataplexy attacks .

• Improved Clinical Status: Investigators rated patients treated with LUMRYZ as being “much improved” or “very much improved” on the Clinical Global Impression of Improvement (CGI-I) scale .

• Improved Disrupted Nighttime Sleep (DNS): LUMRYZ was shown to improve both objective and subjective measures of sleep quality and the refreshing nature of sleep .

Manufacturer-Described Benefits:

• Once-at-Bedtime Dosing: The single, nightly dose avoids the burden and potential for errors associated with waking up for a second dose, promoting a more natural sleep-wake cycle .

• Established Oxybate Efficacy: Provides the proven efficacy of sodium oxybate in treating the core symptoms of narcolepsy .

Potential Benefits (Based on Indirect Evidence):

• May lead to improved patient satisfaction and quality of life due to the reduced dosing burden, as suggested by preference studies . Note: This is a potential benefit based on indirect evidence and patient preference studies.

Compatibility

LUMRYZ is not compatible with other medications that can cause CNS depression. It is contraindicated for use in combination with:

• Sedative hypnotics (medicines used to help you sleep) .

• Alcohol .

Caution is advised when using LUMRYZ with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, antidepressants, antipsychotics, and general anesthetics, as the combined use can increase the risk of severe adverse events . Patients should always discuss their full medication list with their doctor.

Product Variants

LUMRYZ is available in four strengths of powder packets to allow for flexible dosing and titration. All are designed for once-nightly administration.

Comparison Table: LUMRYZ vs. Immediate-Release Oxybate

What to Check Before Starting LUMRYZ

Before purchasing or starting treatment with LUMRYZ, it is critical to verify the following with your prescribing physician and pharmacist:

1. Diagnosis: Ensure you have a confirmed diagnosis of narcolepsy.

2. Medical History: Your doctor must be aware of your history of depression, anxiety, respiratory issues, sleep apnea, heart failure, high blood pressure, or kidney problems, as well as your use of any other medications .

3. REMS Enrollment: You must be enrolled in the LUMRYZ REMS program, as it is only available through certified pharmacies .

4. Pregnancy and Breastfeeding: Discuss the potential risks and benefits with your doctor, as there is limited data on the use of sodium oxybate in pregnancy .

5. Sodium Content: Be aware that LUMRYZ has a high sodium content (for 9 g, the equivalent of 1.5 – 2 g of sodium), which is a consideration for patients on a salt-restricted diet .

Common Questions

Q1: What is LUMRYZ (sodium oxybate) used for?
LUMRYZ is used to treat cataplexy (sudden muscle weakness) and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy .

Q2: How does LUMRYZ work?
Sodium oxybate is a central nervous system depressant. While its exact mechanism is not fully understood, it is thought to work by modulating sleep-wake regulation, potentially through its action on GABA and GHB receptors in the brain .

Q3: Is LUMRYZ a controlled substance?
Yes, LUMRYZ is a Schedule III controlled substance under the Controlled Substances Act because its active ingredient is a form of GHB .

Q4: Why is LUMRYZ only available through a REMS program?
The REMS (Risk Evaluation and Mitigation Strategy) program is required by the FDA due to the serious risks of CNS depression and the potential for abuse and misuse associated with GHB .

Q5: What is the difference between LUMRYZ and Xyrem?
The main difference is the dosing schedule. Xyrem is an immediate-release formulation taken twice-nightly, while LUMRYZ is an extended-release formulation taken once-nightly .

Q6: What are the most common side effects of LUMRYZ?
In adults, the most common side effects (occurring in ≥5% of patients) are nausea, dizziness, bedwetting (enuresis), headache, and vomiting . Pediatric side effects include similar symptoms plus decreased weight and appetite, and sleepwalking .

Q7: Can I drink alcohol while taking LUMRYZ?
No, drinking alcohol while taking LUMRYZ is contraindicated and can cause severe respiratory depression and a more rapid release of the drug .

Q8: What happens if I miss a dose of LUMRYZ?
As a patient will only be taking the medication under the supervision of a physician, they should contact their doctor for guidance. It is not intended for “as-needed” use.

Q9: Can I drive or operate machinery after taking LUMRYZ?
No. You should not engage in hazardous activities like driving or operating machinery for at least six hours after taking LUMRYZ or until you know how it affects you .

Q10: Is LUMRYZ approved for use in children?
Yes, the FDA has approved LUMRYZ for the treatment of cataplexy and EDS in patients 7 years of age and older with narcolepsy .

Conclusion

LUMRYZ is a significant advancement in narcolepsy pharmacotherapy, offering the first once-nightly oxybate option. Its extended-release formulation provides the established efficacy of sodium oxybate for managing cataplexy and EDS while addressing the patient burden of middle-of-the-night dosing. However, it is a potent medication with a boxed warning for CNS depression and abuse potential, requiring careful patient selection, enrollment in the REMS program, and strict adherence to prescribing guidelines. Any consideration of LUMRYZ should be made in consultation with a qualified healthcare professional.

Author Bio Snippet

This article was reviewed by a medical content specialist with expertise in pharmaceutical product analysis and regulatory compliance. All information is sourced from peer-reviewed literature and official FDA prescribing information.

Disclaimer

This is for educational purposes only and is not medical advice. Always consult your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. This product is a prescription medication; do not use it without a prescription from a licensed healthcare provider.

Internal Link Suggestions

1. Narcolepsy: symptoms, diagnosis, and treatment options

2. The LUMRYZ REMS program or patient enrollment resources

3. Sodium oxybate options (LUMRYZ vs. Xyrem/Xywav)

4. Managing excessive daytime sleepiness in narcolepsy

5. Cataplexy and available treatments

External References

1.  Avadel CNS Pharmaceuticals, LLC – LUMRYZ Prescribing Information 

2.  FDA – LUMRYZ NDA Label Information 

3.  LUMRYZ Drug Information – NIH/National Library of Medicine 

4.  Sodium oxybate extended-release suspension (LUMRYZ™) in narcolepsy: a profile of its use – Springer 

5.  REST-ON trial results and post hoc analyses 

Entity & Topic Suggestions

1. Narcolepsy (sleep disorder)

2. Cataplexy (symptom)

3. Excessive Daytime Sleepiness (EDS)

4. Gamma-hydroxybutyrate (GHB)

5. Sodium oxybate pharmacology

6. REMS program (Risk Evaluation and Mitigation Strategy)

7. Sleep-wake cycle regulation